tiprankstipranks
Advertisement
Advertisement

DE:HQ1 Stock Latest News

Oruka Therapeutics price target raised to $78 from $50 at Barclays
The FlyOruka Therapeutics price target raised to $78 from $50 at Barclays
5d ago
ORKA
Oruka Therapeutics price target raised to $75 from $50 at UBS
PremiumThe Fly
Oruka Therapeutics price target raised to $75 from $50 at UBS
6d ago
ORKA
Oruka Therapeutics price target raised to $125 from $60 at Guggenheim
PremiumThe Fly
Oruka Therapeutics price target raised to $125 from $60 at Guggenheim
6d ago
ABBV
ORKA
Oruka Therapeutics files $1B mixed securities shelf
PremiumThe Fly
Oruka Therapeutics files $1B mixed securities shelf
10d ago
ORKA
Oruka Therapeutics price target raised to $86 from $58 at Leerink
PremiumThe Fly
Oruka Therapeutics price target raised to $86 from $58 at Leerink
27d ago
ORKA
Oruka Therapeutics price target raised to $72 from $47 at Stifel
PremiumThe FlyOruka Therapeutics price target raised to $72 from $47 at Stifel
1M ago
ORKA
Oruka Therapeutics price target raised to $50 from $48 at Barclays
Premium
The Fly
Oruka Therapeutics price target raised to $50 from $48 at Barclays
1M ago
ORKA
Oruka Therapeutics reports Q4 EPS (45c), consensus (62c)
Premium
The Fly
Oruka Therapeutics reports Q4 EPS (45c), consensus (62c)
1M ago
ORKA
Is ORKA a Buy, Before Earnings?
PremiumPre-Earnings
Is ORKA a Buy, Before Earnings?
1M ago
ORKA
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
PremiumThe Fly
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
2M ago
GSK
ABBV
Oruka Therapeutics price target raised to $45 from $42 at Wedbush
PremiumThe Fly
Oruka Therapeutics price target raised to $45 from $42 at Wedbush
3M ago
ORKA
Oruka Therapeutics price target raised to $71 from $46 at Clear Street
PremiumThe Fly
Oruka Therapeutics price target raised to $71 from $46 at Clear Street
3M ago
ORKA
Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating
PremiumRatingsOruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating
3M ago
ORKA
Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial
Premium
The Fly
Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial
3M ago
ORKA
Oruka Therapeutics initiated with a Buy at UBS
Premium
The Fly
Oruka Therapeutics initiated with a Buy at UBS
3M ago
ORKA
Oruka Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe Fly
Oruka Therapeutics initiated with an Overweight at Piper Sandler
4M ago
ORKA
Oruka Therapeutics Appoints Christopher Martin to Board
PremiumCompany Announcements
Oruka Therapeutics Appoints Christopher Martin to Board
4M ago
8K
ORKA
Oruka Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Oruka Therapeutics Reports Q3 2025 Financial Results
5M ago
ORKA
Oruka Therapeutics price target raised to $63 from $56 at BTIG
PremiumThe Fly
Oruka Therapeutics price target raised to $63 from $56 at BTIG
5M ago
ORKA
Oruka Therapeutics initiated with a Buy at Jefferies
PremiumThe FlyOruka Therapeutics initiated with a Buy at Jefferies
5M ago
ORKA
Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating
Premium
Ratings
Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating
5M ago
ORKA
Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)
Premium
The Fly
Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)
5M ago
ORKA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >